Immuneering Corporation (IMRX) |
|
4.45 0.04 (0.91%)
|
01-27 16:00 |
|
Open: |
4.39 |
Pre. Close: |
4.41 |
|
High:
|
4.7 |
Low:
|
4.35 |
|
Volume:
|
33,484 |
Market Cap:
|
118(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:29 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 5.84  One year: 6.82 |
| Support: |
Support1: 4.3 Support2: 3.86 |
| Resistance: |
Resistance1: 5 Resistance2: 5.84 |
| Pivot: |
4.34 |
| Moving Average: |
MA(5): 4.38 MA(20): 4.34
MA(100): 8.46  MA(250): 7.21 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 61.9 %D(3): 54.8 |
| RSI: |
RSI(14): 46.3 |
| 52-week: |
High: 16.16 Low: 3.74 |
| Average Vol(K): |
3-Month: 41 (K) 10-Days: 36 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMRX ] has closed below upper band by 38.3%. Bollinger Bands are 78.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.7 - 4.73 |
4.73 - 4.75 |
|
Low:
|
4.3 - 4.32 |
4.32 - 4.34 |
|
Close:
|
4.41 - 4.45 |
4.45 - 4.48 |
|
Company Description |
|
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. |
Headline News |
Thu, 19 Jan 2023
News & Products for the week of January 16th 2023 - TRAINS Magazine
Wed, 18 Jan 2023
7 Cheap But Risky Biotech Stocks - Barron's
Sun, 18 Dec 2022
Immuneering Corporation's (NASDAQ:IMRX) top holders are insiders and they are likely disappointed by the recent 19% drop - Simply Wall St
Thu, 10 Nov 2022
Immuneering Reports Third Quarter 2022 Financial Results and ... - GlobeNewswire
Thu, 20 Oct 2022
Immuneering Appoints Leah R. Neufeld as Chief People Officer - GlobeNewswire
Wed, 05 Oct 2022
Immuneering To Present Poster on IMM-6-415 at the 37th Annual ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
26 (M) |
|
% Held by Insiders
|
1.385e+007 (%) |
|
% Held by Institutions
|
30.5 (%) |
|
Shares Short
|
777 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.867e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-9 |
|
Return on Assets (ttm)
|
657.5 |
|
Return on Equity (ttm)
|
-20.6 |
|
Qtrly Rev. Growth
|
506090 |
|
Gross Profit (p.s.)
|
0.03 |
|
Sales Per Share
|
0.09 |
|
EBITDA (p.s.)
|
-1.09 |
|
Qtrly Earnings Growth
|
-2.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-42 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
45.75 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
882620 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
